HCS Reagents Firm Cellumen Lands Biotech Customer as Part of Screening Services Strategy | GenomeWeb

SAN FRANCISCO — Fledgling high-content screening company Cellumen has landed its first customer as part of its hybrid business strategy to be an HCS service provider as well as a reagent provider, Inside Bioassays has learned.

In an interview conducted at Cambridge Healthtech Institute’s High-Content Analysis conference held here two weeks ago, Lansing Taylor, Cellumen’s CEO, said that Cellumen has forged a partnership with an undisclosed biotech that will serve as a litmus test for its proposed dual business strategy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.